BriaCell Therapeutics

Company snapshot

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for BriaCell Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for BriaCell Therapeutics.

1. May 23, 2026 Clinical update

   SV-BR-1-GM — Phase 3

2. May 23, 2026 Clinical update

   BC1 cell line — Phase 2

3. May 23, 2026 Clinical update

   SV-BR-1-GM — Phase 2

4. Jan 24, 2023 Patent grant

   Whole-cell cancer vaccines and methods for selection thereof

View all clinical trial activity →

• What is BriaCell Therapeutics?

  BriaCell Therapeutics is a pharma organization headquartered in Philadelphia, USA. It trades on NYSE under ticker BCTX. Primary therapeutic focus areas include Breast Cancer, Breastcancer. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 1 patent record(s) to th

• Is BriaCell Therapeutics publicly traded?

  Yes. BriaCell Therapeutics is listed with ticker BCTX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does BriaCell Therapeutics develop or market?

  No drug profiles are currently linked to BriaCell Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for BriaCell Therapeutics?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does BriaCell Therapeutics focus on?

  BriaCell Therapeutics focuses on Breast Cancer, Breastcancer based on our analysis of their pipeline programs and drug development activities.